These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. Badgwell D; Lu Z; Cole L; Fritsche H; Atkinson EN; Somers E; Allard J; Moore RG; Lu KH; Bast RC Gynecol Oncol; 2007 Sep; 106(3):490-7. PubMed ID: 17532030 [TBL] [Abstract][Full Text] [Related]
4. Statistical interpretation of CA125 and Bcl-2 in serum of patients with late stage ovarian cancer. Camlica H; Duranyildiz D; Tas F; Yasasever V Am J Clin Oncol; 2008 Dec; 31(6):585-8. PubMed ID: 19060592 [TBL] [Abstract][Full Text] [Related]
5. The value of serum bcl-2 levels in advanced epithelial ovarian cancer. Tas F; Duranyildiz D; Oguz H; Camlica H; Yasasever V; Topuz E Med Oncol; 2006; 23(2):213-7. PubMed ID: 16720921 [TBL] [Abstract][Full Text] [Related]
6. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients. Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095 [TBL] [Abstract][Full Text] [Related]
7. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951 [TBL] [Abstract][Full Text] [Related]
8. Early detection and prognosis of ovarian cancer using serum YKL-40. Dupont J; Tanwar MK; Thaler HT; Fleisher M; Kauff N; Hensley ML; Sabbatini P; Anderson S; Aghajanian C; Holland EC; Spriggs DR J Clin Oncol; 2004 Aug; 22(16):3330-9. PubMed ID: 15310777 [TBL] [Abstract][Full Text] [Related]
9. Increases urinary HMGA1 in serous epithelial ovarian cancer patients. Zhou J; Xie M; He H; Shi Y; Luo B; Gong G; Li J; Wang J; Wu X; Wen J Cancer Biomark; 2015; 15(3):325-31. PubMed ID: 25586095 [TBL] [Abstract][Full Text] [Related]
10. Urinary MMP-2 and MMP-9 predict the presence of ovarian cancer in women with normal CA125 levels. Coticchia CM; Curatolo AS; Zurakowski D; Yang J; Daniels KE; Matulonis UA; Moses MA Gynecol Oncol; 2011 Nov; 123(2):295-300. PubMed ID: 21889192 [TBL] [Abstract][Full Text] [Related]
11. Urinary concentrations of human epidydimis secretory protein 4 (He4) in the diagnosis of ovarian cancer: a case--control study. Macuks R; Baidekalna I; Donina S Asian Pac J Cancer Prev; 2012; 13(9):4695-8. PubMed ID: 23167404 [TBL] [Abstract][Full Text] [Related]
13. LyGDI is a promising biomarker for ovarian cancer. Zhen H; Yang S; Wu H; Wang S; Lv J; Ma L; Zhang X Int J Gynecol Cancer; 2010 Apr; 20(3):316-22. PubMed ID: 20375790 [TBL] [Abstract][Full Text] [Related]
14. The efficacy of YKL-40 and CA125 as biomarkers for epithelial ovarian cancer. Zou L; He X; Zhang JW Braz J Med Biol Res; 2010 Dec; 43(12):1232-8. PubMed ID: 21103788 [TBL] [Abstract][Full Text] [Related]
15. Alternative tumor markers in the diagnosis of ovarian cancer. Karakaya BK; Başer E; Bildacı B; Cömert EÇ; Bayraktar N; Dursun P; Kuşçu E; Ayhan A Ginekol Pol; 2016; 87(8):565-769. PubMed ID: 27629130 [TBL] [Abstract][Full Text] [Related]
16. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Luo LY; Katsaros D; Scorilas A; Fracchioli S; Bellino R; van Gramberen M; de Bruijn H; Henrik A; Stenman UH; Massobrio M; van der Zee AG; Vergote I; Diamandis EP Cancer Res; 2003 Feb; 63(4):807-11. PubMed ID: 12591730 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of serum mesothelin in malignant and benign ovarian masses. Ibrahim M; Bahaa A; Ibrahim A; El Hakem AA; Abo-El Noor A; El Tohamy U Arch Gynecol Obstet; 2014 Jul; 290(1):107-13. PubMed ID: 24445964 [TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients. Steffensen KD; Waldstrøm M; Brandslund I; Jakobsen A Int J Gynecol Cancer; 2011 Aug; 21(6):1040-7. PubMed ID: 21738039 [TBL] [Abstract][Full Text] [Related]
19. Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer. Leung F; Bernardini MQ; Brown MD; Zheng Y; Molina R; Bast RC; Davis G; Serra S; Diamandis EP; Kulasingam V Cancer Epidemiol Biomarkers Prev; 2016 Sep; 25(9):1333-40. PubMed ID: 27448593 [TBL] [Abstract][Full Text] [Related]